[go: up one dir, main page]

EP0381501B1 - Küvette für eine Polymerase-Reaktion und ihre Verwendung - Google Patents

Küvette für eine Polymerase-Reaktion und ihre Verwendung Download PDF

Info

Publication number
EP0381501B1
EP0381501B1 EP90301061A EP90301061A EP0381501B1 EP 0381501 B1 EP0381501 B1 EP 0381501B1 EP 90301061 A EP90301061 A EP 90301061A EP 90301061 A EP90301061 A EP 90301061A EP 0381501 B1 EP0381501 B1 EP 0381501B1
Authority
EP
European Patent Office
Prior art keywords
compartment
cuvette
dna
detection
compartments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP90301061A
Other languages
English (en)
French (fr)
Other versions
EP0381501A2 (de
EP0381501A3 (de
Inventor
Paul N. C/O Eastman Kodak Co. Schnipelsky
Leonard J. C/O Eastman Kodak Co. Seaberg
Jeffrey A. C/O Eastman Kodak Co. Wellman
Charles C. C/O Eastman Kodak Co. Hinckley
William H. C/O Eastman Kodak Co. Donish
John B. C/O Eastman Kodak Co. Findlay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clinical Diagnostic Systems Inc
Ortho Clinical Diagnostics Inc
Original Assignee
Eastman Kodak Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eastman Kodak Co filed Critical Eastman Kodak Co
Publication of EP0381501A2 publication Critical patent/EP0381501A2/de
Publication of EP0381501A3 publication Critical patent/EP0381501A3/de
Application granted granted Critical
Publication of EP0381501B1 publication Critical patent/EP0381501B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B01L3/502715—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by interfacing components, e.g. fluidic, electrical, optical or mechanical interfaces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B01L3/502707—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by the manufacture of the container or its components
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/10—Integrating sample preparation and analysis in single entity, e.g. lab-on-a-chip concept
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/06—Auxiliary integrated devices, integrated components
    • B01L2300/0627—Sensor or part of a sensor is integrated
    • B01L2300/0636—Integrated biosensor, microarrays
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/06—Auxiliary integrated devices, integrated components
    • B01L2300/069—Absorbents; Gels to retain a fluid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0809—Geometry, shape and general structure rectangular shaped
    • B01L2300/0816—Cards, e.g. flat sample carriers usually with flow in two horizontal directions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
    • B01L2300/0867—Multiple inlets and one sample wells, e.g. mixing, dilution
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
    • B01L2300/087—Multiple sequential chambers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00—Moving or stopping fluids
    • B01L2400/04—Moving fluids with specific forces or mechanical means
    • B01L2400/0475—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure
    • B01L2400/0478—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure pistons
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00—Moving or stopping fluids
    • B01L2400/04—Moving fluids with specific forces or mechanical means
    • B01L2400/0475—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure
    • B01L2400/0481—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure squeezing of channels or chambers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L7/00—Heating or cooling apparatus; Heat insulating devices
    • B01L7/52—Heating or cooling apparatus; Heat insulating devices with provision for submitting samples to a predetermined sequence of different temperatures, e.g. for treating nucleic acid samples
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
    • G01N35/0098—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor involving analyte bound to insoluble magnetic carrier, e.g. using magnetic separation

Definitions

  • This invention relates to cuvettes in which reactions are undertaken to amplify and detect nucleic acids, using polymerase chain reaction technology, without exposing the environment to amplified nucleic acid.
  • PCR Polymerase chain reaction
  • Technology further allows for the detection of the amplified nucleic acid material (DNA for example), using probes which hybridize to the amplified material of choice, such probes in turn either being immobilized or immobilizable to a solid support, such as a filter membrane, and/or being labeled for detection using enzymes or other moieties.
  • amplified nucleic acid material DNA for example
  • probes which hybridize to the amplified material of choice, such probes in turn either being immobilized or immobilizable to a solid support, such as a filter membrane, and/or being labeled for detection using enzymes or other moieties.
  • aerosols are produced in the act of unstoppering the container and/or during transfer of fluids.
  • Such aerosols contain a few molecules of the amplified nucleic acid material, e.g. DNA, become dispersed within the environment. Normally, such few molecules in the environment are not of great concern.
  • DNA amplified nucleic acid material
  • Only one DNA molecule is needed to contaminate other amplifying containers, which are as yet, unused.
  • an errant DNA molecule floats into or is carried, inadvertently, by an operator to another unused amplifying container, that one molecule is all that is needed to provide the DNA needed for the next amplification.
  • a further problem has been in automating the detection steps, and therefore minimizing the need for operator intervention.
  • the need to transfer amplified nucleic acid material or to add detection reagents makes such automation difficult.
  • the invention is based upon the realization that the contamination can be prevented by confining the amplifying reagents and amplified nucleic acid in the cuvette so that it is impossible for any amplified nucleic acid molecules to escape.
  • a disposable cuvette for carrying out amplification and detection of nucleic acid material comprising: a first compartment; a plurality of further compartments, at least one of the further compartments containing material to amplify and detect nucleic acid material; fluid connection means for connecting at least one of the further compartments with the first compartment so that the material retained in the at least one further compartment is transferable to the first compartment when pressure is applied to the material retained in that compartment; a detection site for immobilizing the nucleic acid material for detection after amplification; and thermal transfer means for allowing active or passive cycling of material in the cuvette; characterized in that the first compartment and the detection site are closed to fluid flow to locations outside of the cuvette so that aerosols are not emitted during amplification and detection.
  • apparatus for amplifying and detecting DNA comprising a cuvette containing i) a plurality of compartments and means for interconnecting each of them to at least one other compartment, the compartments including a) at least one reaction compartment for amplifying DNA strands, b) at least one detection compartment for detecting amplified DNA and including a detection site, and c) means for delivering a detection material to amplified DNA strands; ii) means for permitting active or passive cycling of the contents of the reaction compartment through a temperature range of from about 30°C to about 95°C; and iii) liquid access means connected only to the at least one reaction compartment for allowing the injection into the reaction compartment of a sample DNA for amplifying; characterized in that the cuvette further includes iv) means for sealing the cuvette against passage of DNA after sample DNA is injected; and the apparatus further includes means for moving at least the detection material and a DNA strand into the detection compartment and onto the detection site; so that
  • a method for amplifying and detecting nucleic acid material in a closed cuvette comprising the steps of
  • a cuvette is provided for amplifying nucleic acids which avoids the risk of contaminating the environment with amplified nucleic acid since it avoids reopening the area of the cuvette containing such nucleic acid.
  • a cuvette is provided which can be used for such amplification by relatively unskilled labor.
  • the invention is hereinafter described primarily with respect to the use of PCR technology to amplify and detect DNA, using particular preferred cuvette configurations.
  • it is useful with any method of nucleic acid amplification, to amplify nucleic acid from any source, in any cuvette, so long as the apparatus and method prevent amplified nucleic acid from exiting the cuvette in any form.
  • the nucleic acid can be obtained, for example, from plasmids or cloned DNA or RNA, or from natural DNA or RNA from any source, including bacteria, yeast, viruses, cells infected by viruses or bacteria, plants or animals.
  • DNA or RNA may be extracted from blood or tissue materials.
  • transcription-based amplification Another method of amplification called transcription-based amplification, which is different from PCR, can also benefit from the containment cuvette provided according to the present invention. Transcription-based amplification is described in Proc. Natl. Acad. Sci. USA, Volume 86, page 1173-1177, February, 1989 (Biochemistry).
  • Nucleic acid amplification generally proceeds via a particular protocol.
  • One useful protocol is that set forth in US Patent Specification US-A-4683195. Briefly, that protocol features, in the case of DNA amplification, the steps of:
  • primer refers to an oligonucleotide, whether naturally occurring or synthetically produced, which is capable of acting as a point of initiation of synthesis when placed under conditions in which synthesis of a primer extension product complementary to a nucleic acid strand is induced. Such conditions include the presence of nucleotides (such as the four standard deoxyribonucleotide triphosphates) and an agent for polymerization such as a DNA polymerase, and suitable temperature and pH. Generally, each primer used in this invention will have from 15 to 40 nucleotides, and preferably, it has from 20 to 25 nucleotides.
  • the cuvette of the present invention provides a practical approach to allowing PCR technology to be practiced routinely by technicians and those of lesser skills, in an accurate fashion. For a complete understanding of the invention, further details of the PCR technology as it is practiced with this invention will be enumerated first.
  • Any DNA can be selectively replicated hundreds of millions of times. Selection of the appropriate primer nucleic acid strands insures that, under the best conditions, primarily the DNA of choice will replicate. Preferably, all primers are biotinylated when incorporated into the cuvette, to allow detection to proceed as described later. Heating of the target DNA now attached to a primer in the presence of an extension enzyme, produces a double strand which includes a copy of the DNA of choice. The new pair so formed is then separated by very short periods of high temperature denaturing, and the process repeated.
  • the primers, deoxyribonucleotides and extension enzymes are present when the sample is added, either as pre-incorporated reagents or reagents which are added with the DNA.
  • the reagents can be applied by spraying and drying, and can include a polymerase, salts, buffers, stabilizers, and the nucleotides needed for replication.
  • the polymerase enzyme is useful regardless of its source.
  • it is the polymerase naturally produced from Thermus aquaticus, hereinafter "TAQ", or any synthetic equivalent such as that which is genetically engineered, as described, for example, in published European patent application EP-A-0258017.
  • TAQ Thermus aquaticus
  • the presence of the enzymes emphasizes the need for rapid thermal cycling and short residence times at high temperatures.
  • the denaturing temperature of between 92° and 95°C is close to the deactivation temperature of the enzymes, thus rendering unsatisfactory long heating periods.
  • the replicated DNA is identified, preferably by moving it to a detection compartment, to which suitable detection material is added or contained therein.
  • suitable detection material is added or contained therein.
  • the detection involves the use of conventional materials capable of bonding via a complementary sequence of nucleotides to a replicated DNA strand.
  • Such materials also include appropriate means which can be used to trap and hold the DNA at a detection site, such as in a detection compartment.
  • such appropriate means feature a membrane and/or a bead which is trapped.
  • Detection requires generally an immobilizing material and a signal generating material.
  • a primer used to replicate the DNA is alreayd biotinylated, so as to react with avidin which is attached to either the immobilizing material or the signal-generating material. If the avidin is attached to the immobilizing material (such as a bead), hereinafter, the "avidin-bead capture” method, then a detection probe is used with a nucleotide sequence which hybridizes with replicated primer and which either itself generates a signal (for example, by being radioactive), or reacts with a reagent which produces a signal.
  • the detection probe can be attached to any appropriate signal-generating moiety, preferably enzymes, for example, horseradish peroxidase, capable of reacting with a leuco dye to produce a detectable signal (e.g. a color change).
  • a signal generating moiety or an immobolizing material to a probe at the 3′ or 5′ end is known. For example in "Efficient Methods for Attachment of Thiol Specific Probes to the 3′ End of Synthetic Oligodeoxyribonucleotides", Vol. 15 of Nucleic Acids Research, p. 5303 (1987), the techniques useful for the 3′ end attachment are discussed.
  • probe refers to an oligonucleotide naturally occurring or synthetically produced, which does not act like a primer, but which is designed to be substantially complementary to one or more sequences of a nucleic acid so as to form a hybridized product. Further, a probe is generally designed for either “capture” or “detection” of the resulting hybridized product.
  • the detection probe and the immobilizing probe can be one and the same, attached at, say, just the 5′ end, using the techniques taught in the aforesaid Analytical Biochemistry article.
  • the avidin can be attached to the signal-generating material, such as horseradish peroxidase, hereinafter the "oligo capture” method.
  • the immobilizing of the DNA is preferably achieved by an immobilizing probe, which is a nucleotide sequence which hybridizes with the replicated biotinylated primer, such sequence being attached to a polymer bead.
  • detection material includes a probe on the replicated, biotinylated primer, which either itself generates a detectable signal or reacts with a reagent to produce a detectable signal. In the latter case, the detection material also includes such reagent.
  • the cuvette containing all detection materials, as well as the amplified DNA can be agitated or shaken to promote mixing, and annealing of probes to the targeted DNA is achieved by conventional temperature cycling.
  • the hybridizing of the probes to the DNA can be done prior to or after transfer, if any, to the detection site.
  • the final step is to inject into the detection compartment a liquid containing a leuco dye or some other dye precursor capable of reacting with the detection material projecting from the DNA strands captured on the membrane.
  • a leuco dye or some other dye precursor capable of reacting with the detection material projecting from the DNA strands captured on the membrane.
  • leuco dyes include those disclosed in US Patent Specification US-A-4089747, preferably in combination with a solubilizing polymer such as poly(vinyl pyrrolidone).
  • a preferred example of the dye is 2-(4-hydroxy-3,5-dimethoxyphenyl)-4,5-bis(4-methoxyphenyl)imidazole, since this gives about 1000 dye molecules per 1 molecule of horseradish peroxidase.
  • the DNA can attach to or be hybridized to a probe on a bead.
  • the beads are selected to be trapped by the detection membrane.
  • Useful material for such beads includes any polymer which has useful reactive groups for bonding to either avidin or to a probe which will hybridize to the DNA.
  • Conventional covalent attachments of avidin via active halogen atoms, 2-substituted activated ethylsulfonyl, or vinylsulfonyl groups on such polymers are known.
  • copolymers of m and p -(2-chloroethylsulfonylmethyl)styrene are useful, for example, for such beads.
  • the first is to use an efficient thermal transfer so that the contents of the reaction compartment are quickly heated and then quickly cooled.
  • Means permitting either active or passive heating and cooling are useful, providing active or passive cycling.
  • a Peltier device can be mounted in the reaction compartment to provide a heat transfer wall bordering the compartment.
  • the heat transfer is achieved by passive means, wherein the heat transfer material is a major wall surface of the reaction compartment.
  • the heat source or heat sink is then supplied from an exterior source, most preferably on both sides of the cuvette.
  • the second key aspect is to construct the cuvette compartments to prevent amplified nucleic acid from escaping, namely, the compartments must be sealed against leakage to the environment once amplification occurs.
  • a preferred construction is one in which the compartments have pre-incorporated all reagents before DNA is introduced, and locking means are used to lock the cuvette against leakage after DNA introduction.
  • means are provided for bringing about liquid communication between compartments within the closed cuvette, preferably using applied pressure, to obtain the necessary reactions.
  • This mechanism transfers heat and/or cools a sample containing a nucleic acid material, such as DNA, to produce the amplification required for detection of that particular nucleic acid material.
  • the material of the transfer wall is selected to provide a predetermined thermal path length and thermal resistance which will provide a high rate of thermal energy transfer. Most preferably, such path length is no greater than about 0.3mm, and the thermal resistance for a cross-sectional area of 1cm2 is no greater than about 5.0°C/W.
  • These properties are readily achieved by constructing the thermal transfer wall out of a plastic, or a laminate of plastic and metal, e.g. aluminium, which is about 0.05mm thick.
  • the thermal transfer wall can be secured to any of the other cuvette walls by any suitable means.
  • a suitable means is a layer of a priming adhesive, which comprises, for example, a conventional high temperature acrylic adhesive, followed by a layer of conventional polyester adhesive.
  • a priming adhesive comprises, for example, a conventional high temperature acrylic adhesive, followed by a layer of conventional polyester adhesive.
  • These adhesive layers can extend over the surface area of the thermal transfer wall, as such extensions can prevent the aluminium, if used, from interfering with reactions occurring within the cuvette.
  • a plastic layer can cover the aluminium.
  • a cuvette constructed with such a thermal transfer wall has been found to produce a thermal time constant, ⁇ , for a volume of liquid of about 200»l, which is no greater than about 10s. Most preferred are those values for which ⁇ is of the order of 3 to 8s.
  • ⁇ is of the order of 3 to 8s.
  • the heat source can be a defocused laser.
  • the use of just a clear polyester layer as the thermal transfer wall is preferred in such a case, and a dye is incorporated into the reaction compartment, having an absorption wavelength appropriate to the laser.
  • the amplified DNA must be locked within the cuvette.
  • reagent needed for amplifications that is, the primer strands, deoxyribonucleotides and the extension enzymes, are either pre-incorporated into the cuvette prior to addition of the sample of nucleic acid material, or they are added with the sample.
  • the detection material is pre-incorporated prior to addition of the sample, so that after sample addition and prior to amplification, the cuvette is locked shut against leakage, there being no further access required.
  • the cuvette can be constructed to allow the detection material to be added to storage compartments post amplification, subject to these provisions:
  • the cuvette is provided with means for providing communication between the storage compartments and the detection compartment.
  • communications means include means such as pressurizing members for moving the reagents from the storage compartment to the detection site, for example, a separate detection compartment.
  • the pressurizing means are exterior to the cuvette, and the walls of the cuvette are flexible enough to transmit pressure from the exterior to the interior, thus pressurizing and moving the reagents within the cuvette.
  • Any external pressure source can be used, e.g. a pressure roller or a piston from an air cylinder.
  • FIGs 1 to 5 illustrate one embodiment of a cuvette 10.
  • the cuvette 10 has flexible compartments which can cooperate with external pressurizing means 60, to provide the total apparatus of the present invention. More particularly, the cuvette 10 comprises two relatively thin sheets 12, 14 which are formed by molding them with pockets or compartments 26, 30, 32, 34, 36, 38, 40, 42, and connecting passageways 44, 48, 50, 52, 54 which protrude from the plane in which the sheets 12, 14 contact one another (see Figure 2).
  • the sheets 12, 14 are secured together at least along their outer periphery 16, and preferably at all points surrounding compartments or passageways, such as by heat- and/or ultrasonic pressure-sealing.
  • a heat-activatable adhesive such as ethylene vinyl acetate is useful for such joining operation.
  • a liquid injection aperture 22 is the exception to the sealed periphery 16, for use with a mating pipette 24.
  • Such aperture 22 optionally includes a rigid rim 23 extending into it within which a pipette 24 seats as is shown in Figure 4.
  • Compartment 26 is a reaction compartment in which amplifying reagents 28 in liquid or dried form may optionally be pre-incorporated as shown in Figure 2.
  • Compartment 30 is a storage compartment for a first wash of the process and contains wash water as a pre-incorporated reagent.
  • Compartment 32 is another storage compartment and contains at least one of the detection materials pre-incorporated therein, namely a biotinylated probe having at one end a complementary nucleotide for attachment to the amplified DNA.
  • a signal generating moiety for example, avidin bound to the horseradish peroxidase as discussed above is also pre-incorporated into storage compartment 32.
  • Compartment 34 is a storage compartment for a second wash. Preferably, this compartment has a much larger volume than that of compartment 32.
  • Compartment 36 has the remaining detection reagents pre-incorporated therein. These are a peroxide and a leuco dye, for example 2-(4-hydroxy-3,5-dimethoxyphenyl)-4,5-bis(4-methoxyphenyl)imidazole, preferably in combination with poly(viny pyrrolidone) as a stabilizer.
  • a peroxide and a leuco dye for example 2-(4-hydroxy-3,5-dimethoxyphenyl)-4,5-bis(4-methoxyphenyl)imidazole, preferably in combination with poly(viny pyrrolidone) as a stabilizer.
  • Compartment 38 has a stop solution pre-incorporated therein which prevent too much leuco dye from converting to the dye.
  • This stop solution may be, for example, a solution of sodium azide
  • Compartment 40 contains the detection site (39) for the cuvette of this embodiment, and will be described later.
  • Compartment 42 is the waste compartment, which is, preferably initially deflated to provide for expansion as liquid is forced into it.
  • Compartment 26 connects to compartment 40 via passageway 44.
  • a one-way check valve (not shown) can be included in passageway 44 to prevent waste liquid from backwashing into compartment 40, thus creating undesirable background color.
  • Passageway 21 connects injection aperture 22 with reaction compartment 26, and passageway 44 connects reaction compartment 26 with detection compartment 40, except that a temporary seal is provided at 46 to keep introduced DNA in compartment 26 until pressure is generated by roller 60.
  • Compartment 30, compartment 32, compartment 34, compartment 36, and compartment 38 are all connected with detection compartment 40 by means of respective passageways 48, 49, 50, 52, and 54.
  • Each compartment is preferably provided with a temporary seal 56 for interrupting flow out of the respective compartment until roller 60 breaks the seal. The position of the seal 56 is is shown in Figure 2.
  • Passageway 54 serves as the trunk line to which the other passageways 48, 49, 50 and 52 are joined.
  • compartments are deliberately positioned, as shown in Figure 1, so that each one will empty into compartment 40 in the proper sequence as roller 60 advances along path A in the direction of arrows 'X'.
  • the sequence is as follows:
  • the development of the dye from the leuco dye needs to be carried out in the dark, for example, if the dye fades readily in light.
  • the respective passageways are also preferably constructed so as to be squeezed by the roller, in particular, they are constructed to always form an angle to arrows X that is less than a right angle, within path A of roller 60. If they were to form a right angle, the roller would tend to jump over the passageway, rather than squeeze it.
  • sheet 12 can comprise a collapsible, relatively flexible plastic such as a heat-sealable polyester, for example ScotchpakTM brand heat-sealable film no.229 made by 3M, whereas sheet 14 can be less flexible and less collapsible, or it can be of the same flexibility as sheet 12.
  • a collapsible, relatively flexible plastic such as a heat-sealable polyester, for example ScotchpakTM brand heat-sealable film no.229 made by 3M
  • sheet 14 can be less flexible and less collapsible, or it can be of the same flexibility as sheet 12.
  • Sheet 14 may comprise a laminate at least for compartment 26.
  • the laminate comprises an aluminium foil 64 on the outside, and a polymer layer 66 on the inside, as shown in Figure 5.
  • the polymer layer 66 is a layer of polyester, similar to sheet 12.
  • the aluminium foil preferably has a thickness of between about 0.0013cm and about 0.026cm, and most preferably about 0.005cm.
  • Layer 66 has a thickness of between about 0.0013cm and about 0.03cm, and most preferably about 0.005cm. Even with layer 66 present, the thermal path length of compartment 26 is no more than about 0.3mm and the thermal resistance does not exceed about 5.0°C/watt.
  • sheet 14 preferably constructed as a laminate for the entire length of cuvette 10.
  • pinching means can be used to pinch off the passageways as follows:
  • a prewash compartment can be included, as shown in a second embodiment of a cuvette 10A illustrated in Figure 6. This ensures that all the exit passageways are first filled with water, so that upstream compartments will not backwash into the passageways for downstream compartments. Parts similar to those previously described, bear the same reference numeral to which the distinguishing suffix "A" has been appended.
  • the very first compartment to be encountered by roller 60 can be storage compartment 61 containing wash water which empties via passageway 62 to trunk line 54A.
  • the rest of the passageways 44A, 48A, 49A, 50A and 52A all connect from their respective compartments as described previously.
  • the injection passageway 21A and aperture 22A for compartment 26A are moved to the opposite edge of cuvette 10A, because of compartment 61.
  • the function of compartment 61 and passageway 62 is to flood all passageways of all the compartments with wash water, when the roller flattens that compartment.
  • Compartment 61 can provide an additional advantage of allowing re-constitution of dried reagents stored in compartments 32A, 36A and 38A. If the light heat seal used (as hereinafter described) to close off the exit of each compartment to its respective passageway is omitted and dried reagents are stored in their respective compartments, when compartment 61 is pressurized by the roller 60, water from compartment 61 will flood the cuvette 10A and reconstitute the dried reagents stored in compartments 32A, 36A, and 38A. 0ptionally, this can be aided by shaking the cuvette. The reconstitution step can occur before or after sample injection into the reaction compartment or amplification within the reaction compartment.
  • the two embodiments described above feature sequential pressurization of each of the compartments.
  • simultaneous pressurization of all the liquid containing compartments can be used, provided that pinch points P1, P2, P3, P4 and P5, in Figure 1, are also used. If pressure is applied to all of P1, P2, P3, P4 and P5 to close off the exit passageways except for passageway 44, pressure can be simultaneously applied (for example, by appropriately placed air pistons) to all of compartments 26, 30, 32, 34, 36 and 38. However, since only passageway 44 is unblocked, only the amplified DNA will be transferred to the detection compartment 40. Thereafter, the pinch points are released in sequence.
  • Detection compartment 40 is a flow-by compartment comprising a detecting member 39 which comprises a supporting sheet 41 on which are disposed piles 43, 43′, 43 ⁇ , and 43′′′. If the oligo capture method is being used, then each pile 43, 43′, 43 ⁇ , and 43′′′ comprises polymer beads to which the detection probes noted above are immovably attached.
  • the detection probes are constructed to hybridize with the DNA so that it can be detected. Most preferably, each bead has a different detection probe for a different DNA, so that if enough different piles of beads are present, for example, 8 to 10, tissue typing can be carried out on the basis of seeing which beads change color due to the dye from compartment 36. It is conventional to use latex beads in such an application.
  • Sheet 41 is made from a material which will bond to the pile of beads, keeping them in place once they have been deposited and dried during manufacturing.
  • materials from which sheet 41 could be made include nitrocellulose, porous nylon membranes such as those manufactured by Pall Corp., and most preferably a paper coated with latex.
  • An example of such a latex coated paper comprises a paper weighing about 54g/m2 and having a thickness of about 0.6mm, with a neutral internal sizing, made from about 80% hardwood, can be surface sized and then coated with a latex coating at an average of about 7g/m2.
  • the coating is composed of a conventional industrial grade latex, NaOH at 20 weight %, TSPP as a dispersing agent, opacifying agents such as silicon dioxide and titanium dioxide, hydrasperse clay, and the rest distilled water.
  • the sheets 12 and 14 are prepared and assembled as follows: sheet 14 is premolded with the compartment indentations formed as shown in Figures 1 and 2. With sheet 14 turned upside down, the indentations forming cups, reagents can be then applied, for example dried reagents 28 and the liquids that go into compartments 30, 32, 34, 36 and 38. Next, sheet 12, now an "upper” sheet, is superposed while essentially flat, except for the mating depression shown at 26' in Figure 2. The two sheets are then lightly anchored together around the perimeter of each compartment as shown by hatching lines in Figure 1, except at the junction 25 of passageway 21 with compartment 26.
  • a light heat-sealing will bond the two plastic sheets together at these portions, including the outlet of each compartment to its respective exit passageway to provide the temporary seal 56.
  • Each temporary seal 56 prevents liquid proceeding out of a compartment once it is introduced. However, this seal 56 is overcome when roller 60 is applied. (Such temporary seals appear as a broken line at the cross-section of passageways 48, 49, 52 and 54 as shown in Figure 2, and represent a site of separation when liquid is forced out of the compartments.)
  • a heavy seal e.g., a heat seal
  • a heavy seal is applied around the circumference of each compartment and its exit passageway, but not across the junction of the passageway to the compartment, that is the operation of the temporary seal 56 is not affected.
  • the heavy seal is also applied to the outer periphery 16. The sealing around compartments ensures that liquid pressed out of the compartments will flow only along the respective passageways and not elsewhere between sheets 12 and 14.
  • the patient sample S is injected into compartment 26, as shown in more detail in Figure 5, via a pipette 24, at aperture 22. This causes depressed portion 26' to "pop out” enough to become about flush with the rest of sheet 12, shown in phantom in Figure 2 and in solid line in Figure 5.
  • portion 26' can be forced to "pop out” beyond the plane of the rest of sheet 12, to form an opposite blister 26", as shown in Figure 19.
  • sheets 12 and 14 need not have any metallic component or layer, and can consist entirely of plastic, that is, a plastic sheet alone can provide sufficient rates of thermal transfer.
  • aperture 22 it is essential that aperture 22, as shown in Figures 1 and 4, be closable after pipette 24 is withdrawn, and prior to the amplification step. This can be accomplished by heat-sealing the aperture closed, or by stoppering the aperture in a suitable fashion, such as by heat-sealing strips 12 and 14 with the heavy seal, or constructing rim 23 with a one-way valve, not shown. If aperture 22 is to be heat-sealed, preferably rim 23 is omitted and pipette 24 is simply pushed directly into the aperture. Whatever mode of closure is used, it should be effective to resist any pressure build-up during PCR amplification or during liquid transfer. However, heat-sealing is the preferred method.
  • heating and cooling to provide the needed thermal PCR cycling preferably occurs by heating one or both strips 12 and 14 at compartment 26.
  • the amplified DNA When the amplified DNA enters compartment 40, it is retained there briefly while heat is applied through strip 14 to effect hybridization.
  • strip 14 is transparent at compartment 40 to allow transmission of radiation of suitable wavelength, e.g., visible wavelengths to allow examination of the contents.
  • Compartment 42 can expand to accommodate the liquid influx as well as air influx, since it is preferably deflated prior to use.
  • the instruments used to process the cuvette can include a vacuum plate which pulls compartment 42 out to its inflated shape when the waste volume is needed.
  • Cuvette 10B has all the compartments 26B, 30B, 32B, 34B, 36B, 38B, 40B, and 42B as before, with their passageways interconnecting them so as to function as before. However, each and every one has a liquid injection aperture 70 at the periphery 16B providing, with connecting passageway 72, a fluid path from the atmosphere to the respective compartment. In such a construction, only compartment 26B has liquid in it at the time of DNA amplification, namely sample DNA and the amplifying reagents. (Its injection aperture 22B is closed at this time.) The other compartments can be left open, because of the temporary heat seals formed at their junction with their exit passageways.
  • a check valve 80 can be inserted into passageway 54B to prevent a backwash of DNA into those compartments.
  • a valve is conventional, and can comprise, for example, a ball valve comprising a seat 82 and a ball 84 as shown in Figure 8.
  • the ball 84 when pushed back upstream, seats on seat 82 to stop flow. Ball 84 is free, however, to flow downstream and its amount of travel is limited by a small stop 86.
  • Valve 80 is preferably located in trunk passageway 54B, as shown in Figure 7, since this allows one valve to serve all the storage compartments, and it is out of the way of path A, that is, it does not represent an obstacle to the passage of the pressure roller.
  • each aperture 70 is closed tightly in a manner similar to the closure of aperture 22B.
  • apertures 70 can be used as a fill technique to pre-incorporate all the reagents.
  • the means for moving the liquids containing, for example, amplified DNA and the detection material is a piston in a piston chamber, instead of a collapsible flexible wall of the compartments.
  • the piston chamber forms the appropriate compartment, and the pistons are the equivalent of the flexible walls of the compartments.
  • the piston-piston chamber arrangement can also be used for fluidly interconnecting all the compartments.
  • a cuvette 100 comprises a reaction compartment 126 having a thermal transfer wall 114, as shown in Figures 10 and 12, a detection material storage compartment 132, a wash storage compartment 134, a leuco dye storage compartment 136, a stop solution storage compartment 138, and another wash storage compartment 139.
  • Each compartment 126, 132, 134, 136, 138, 139 has an associated passageway 144, 149, 150, 152, 154, 156 connected to it.
  • Thermal transfer wall 114 is preferably constructed as described previously.
  • Each storage compartment 132, 134, 136, 138, 139 functions as a piston chamber.
  • a piston 113, 115 mounted within each chamber is a piston 113, 115, which is disposed outside of the reagent in the compartment, that is, along an edge of the cuvette 100.
  • the pistons are double-sealing as shown, and include means such as a slot (not shown) for positively engaging a driver actuator for that compartment (not shown).
  • Passageways 149 and 150 are connected together to form passageway 151, as shown in Figures 9 and 12.
  • This passageway 151 connects with reaction compartment 126.
  • a DNA sample is fed to the reaction compartment 126 via passageway 121 from liquid ingress aperture 122.
  • This aperture is provided with an exterior shoulder 123, see Figure 9.
  • Passageways 152, 154 and 156 join together, as shown in Figure 12, to form passageway 155 into which passageway 144 feeds from compartment 126, see Figure 9. Passageway 155 then branches to form passageway 157 which leads to compartment 140, and a vent passageway which exits at 159 within shoulder 123. Shoulder 123 is internally threaded (not shown) to receive an externally threaded stopper (also not shown). The ingress aperture 122 and vent aperture 159 can both be sealed off by the stopper.
  • piston 184 and piston chamber 182 are provided to allow air expansion from detection compartment 140.
  • This piston-piston chamber arrangement 184, 182 is shown in Figures 9, 11 and 12. Chamber 182 is connected via passageway 185 to the bottom of compartment 140. This can be done by manually withdrawing piston 184 within its chamber. A stem 187 can project from piston 184 for assisting in withdrawal of that piston.
  • flow-through detection compartment 140 has an upper portion 190, into which liquid first enters as it is transferred from other compartments, and a lower portion 192, as shown more clearly in Figure 10, separated from the upper portion by a permeable membrane 194.
  • Lower portion 192 is substantially filled by an absorbent member 196, which is intended to absorb all the excess liquid which enters compartment 140.
  • Membrane 194 is preferably a cast, woven or electrooptically machined, microfiltration membrane. Any suitable material can be used for absorbent member 196, for example, cellulose acetate.
  • Membrane 194 functions to aid in separation of free, unreacted detection label, from those hybridized to the DNA.
  • the detection probes in compartment 132 are designed both to hydridize onto amplified DNA in compartment 126, and to attach to membrane 194 (or to beads which are trapped by the membrane) once the liquid reaches compartment 140.
  • Such probes also include a label such as horseradish peroxidase, which reacts with the leuco dye and peroxide when those materials reach compartment 140.
  • Filling of compartments 132, 134, 136 and 138 can be achieved by adding liquid and then inserting the pistons.
  • prepackaged ampules (not shown) can be inserted, followed by the pistons, the ampules being frangible so that as pressure is applied by the piston, the ampule breaks open to release the liquid.
  • Transfer of liquid in cuvette 100 is controlled by the pistons 113, 115, and 184, piston 184 being used to create the vacuum which allows the other pistons to advance.
  • an additional compartment and associated piston can be included to feed additional enzyme into compartment 126, so that any deactivation of enzyme by the denaturing step can be countered by the addition of more enzyme.
  • cuvette 100 Use of cuvette 100 is as follows:- The pistons 113, 115, 184 start in the positions as shown in Figure 9.
  • Sample DNA is introduced via a pipette at aperture 122, and passes through passageway 121 into compartment 126.
  • the amplification reagents may already be present, or they may be co-introduced with the DNA.
  • the vent aperture 159 and passageway 155 allow the air in compartment 126 to be pushed out by the advancing liquid.
  • a stopper is then inserted into shoulder 123, sealing off apertures 122 and 159.
  • Thermal cycling is carried out on compartment 126, using thermal transfer wall 114, until the desired DNA amplification is achieved. Up until this point, the pistons have not been moved.
  • compartment 126 the contents of compartment 126 preferably include polymer beads to which is bound a biotinylated primer capable of extending with the amplified DNA in an annealing step, the primer being bound via avidin, to copy the amplified DNA.
  • the compartment 126 also includes a detection probe, that is, a nucleotide constructed to hybridize with the extended primer attached to a moiety such as horseradish peroxidase.
  • Mixing can then be achieved by agitating the entire cuvette by any conventional means.
  • the detection probes are then hydridized to the amplified DNA in compartment 126 by applying thermal control in conventional steps, through thermal transfer wall 114, for example, by heating at 42°C for five minutes.
  • the leuco dye of compartment 136 and then the stop solution of compartment 138 are advanced into passageways 155 and 157 and then into compartment 140. This is achieved by advancing their respective pistons 113. This will cause appropriate dye formation at membrane 194 if the amplified DNA is present. (If it is not present, since all free detection material has already washed through into absorbent member 196, no color will form and the test will indicate "negative".)
  • cuvette 100C has compartments 126C, 132C, 134C, 136C, 138C and their passageways leading to and from each other and from ingress aperture 122C as before.
  • Pistons 113C, 115C and 184C are used to transfer liquid as before, after the DNA amplification as described earlier.
  • compartment 132C includes as detection reagents, magnetic beads formed from polymers containing magnetic fillers, to which have been bonded the hydridizing material with matching DNA sequences. This is intended to hybridize to one end, for example, of the amplified DNA. The other end of that amplified DNA is intended to hybridize to a detection probe bearing the horseradish peroxidase, as described above.
  • separation of the free detection probes not yet hybridized to DNA is achieved as follows:- When wash solution is injected from compartment 134C, a magnetic field is supplied below compartment 126C, to retain the bead reagents and any detection probe hydridized to an amplified DNA. This causes free detection probes and their labels to be washed out of compartment 126C and into chamber 182C, in which piston 184C has been withdrawn to make room. The magnetic field is further maintained while the leuco dye and the stop liquids are transferred into the reaction compartment 126C, causing color to form there if any amplified DNA is present.
  • the cuvette is preferably constructed as shown in Figure 14. Parts similar to those previously described bear the same reference numeral, to which the distinguishing suffix "D" is applied.
  • Cuvette 100D has the same compartments 126D, 132D, 134D, 136D and 138D as before, with pistons 113D being used in the storage compartments. Shoulder 123D protects liquid ingress aperture 122D, and detection is done at a membrane (not shown), all as discussed before. However, passageway 121D, instead of delivering the pipetted liquid sample direct to the reaction compartment 126D, it delivers it to an extraction compartment 200.
  • the liquid sample in this case is whole blood or a solution of blood cells, from which the DNA is to be extracted. At the time this liquid sample is added to the cuvette, extracting agents discussed below can be optionally added. Alternatively, they can be pre-incorporated into compartment 200.
  • a piston 113D is used in compartment 200, as with the other similar compartments, except that it is fully withdrawn, as shown, to provide maximum room for the introduced sample.
  • Passageway 121D enters compartment 200 at a point 201 just below piston 113D.
  • a passageway 204 fluidly connects to an intermediate compartment 206, in which is disposed a filter 208 which the liquid must traverse, in order to reach compartment 126D.
  • Filter 208 has pore sizes adequate to retain cellular fragments in the filter and to pass extracted DNA.
  • a filter made of nylon or polypropylene with pore sizes of about 0.45 »m is particularly useful.
  • a passageway 210 carries extracted DNA and solvent (e.g., water) into compartment 126D.
  • solvent e.g., water
  • the liquid sample is injected into compartment 200, preferably along with extraction agents, if any.
  • Any DNA extraction protocol can be used, along with concommitant extraction agents, such as surfactants.
  • Highly preferred is a simple heating of the solution to a temperature of about 95°C for about 5min. Such heating is effective to denature the proteins and lyse the cells.
  • dextran can be optionally added as a 3wt% solution, along with a 10wt% solution of TX-100 (Registered TM), which is a non-ionic surfactant available from Rohm and Haas.
  • the heating of compartment 200 can be more rapidly achieved by constructing at least a portion 220 of the wall of the compartment from aluminium. The aluminium extends to the bottom exterior of the cuvette (not shown as a separate surface), and the application of heat to this region of the cuvette adjacent compartment 200 is thus effective to heat compartment 200.
  • compartment 200 After a suitable incubation period, the contents of compartment 200 are pushed to filter 208 by advancing piston 113D.
  • Figures 15 and 16 are illustrative of a modification which provides this. Parts similar to those previously described bear the same reference numeral, to which the distinguishing suffix "E" is applied.
  • a cuvette 100E has compartments 126E, 136E, 138E and 182E as before, with appropriate pistons 184E, etc.
  • a passageway 121E carries liquid sample from aperture 122E to reaction compartment 126E, and passageway 151E also feeds liquid to that compartment.
  • Biotinylated primers are delivered from a suitable location, and leuco dye and stop solution are delivered via passageways 155E and 157E to the detection site.
  • Passageway 144E provides access of the DNA product produced in compartment 126E, to those passageways 155E and 157E. Liquid coming from passageway 157E encounters a detection membrane 194E disposed in contact with absorbent member 196E, as shown in Figure 16, This is as described with reference to the previous embodiments.
  • the sample DNA detection there are separate regions at membrane 194E for the sample DNA detection, labeled "S"; for a positive control, labeled "+”; and for a negative control, labeled "-", as shown in Figure 15.
  • the purpose of the positive control is to ensure that the reagents will produce a signal for DNA (preferably a color), if the DNA is present. This alerts the user if the reagents are defective in any way by failing to produce a signal at the "+" region.
  • the negative control on the other hand should not produce a signal.
  • the primary purpose of the negative control is to give the user a background color against which the sample color is to be compared. For example, a faint background color may occur in the reagents for extraneous reasons, and it is important that the sample color be significantly greater in density than this, before a "positive" read is attributed to the test.
  • the method used is the avidin-bead capture.
  • This method features the use of avidin or streptavidin covalently attached to beads, biotinylated primers, and labeled detection probes as part of the detection material.
  • Preferably at least the probes are kept in storage compartments 250, 252 and 254. Each compartment is dedicated to a single type of detection probe.
  • Compartment 250 has the sample DNA probes, 252 the negative control probes, and 254 the positive control probes.
  • Pistons 260 are used to pressurize their respective compartments, preferably simultaneously, to force the contents out through respective passageways 262, 264 and 266 into the detection compartment 268, 270 and 272 associated with each probe and each probe passageway. In this way, each detection compartment has only its probe in it, and none of the other two.
  • passageway 157E preferably splits into three branches 274, 276, and 278 which connect with the respective detection compartments 268, 270, 272.
  • the probe for the sample has a genetic complement to the targeted DNA of the sample.
  • the positive probe has a genetic complement for a DNA material which is always present, which at least in the case of blood cells, is preferably beta-globin.
  • the negative probe has a genetic complement which matches no known amplified DNA from the sample. This is done most easily by constructing the probe complement with any genetic code which is random in sequence, hence a "nonsense" code.
  • the avidin-bearing beads are preferably stored with the probes in compartments 250, 252 and 254.
  • amplified DNA is supplied via passageways 274, 276 and 278 to the respective detection compartments, pistons 260 are advanced to push the appropriate probes and beads into those detection compartments.
  • Those compartments are appropriately heated to cause the amplified DNA to hybridize specifically in compartments 268 and 272 to the appropriate probe from compartments 250 and 254.
  • no hybridization occurs in detection compartment 270, since there should be no "nonsense" DNA present to react with the negative control probe.
  • Wash solution is then pushed through the detection compartments to wash any labeled probes not hybridized and thus not attached to beads into the absorbent member 196E through membrane 194E.
  • the wash is followed by contact with the leuco dye solution, and then contact with the stop solution.
  • oligo capture technique Another method which can be used is the so-called oligo capture technique.
  • the labeled probes are stored in immobilized form, already on the detection membrane prior to the introduction of amplified DNA. Parts similar to those previously described bear the same reference numeral, to which the distinguishing suffix "F" is appended.
  • the oligo capture method used in this embodiment features probes immobilized either on the membrane, or on the above-mentioned beads which are trapped on or in the membrane, such probes containing genetic material which is complementary to the appropriate DNA.
  • probes immobilized either on the membrane, or on the above-mentioned beads which are trapped on or in the membrane such probes containing genetic material which is complementary to the appropriate DNA.
  • labeled avidin for reaction with biotin on the amplified DNA is stored for which the label can be, for example, horseradish peroxidase.
  • cuvette 100F is identical to that of the embodiment of Figure 9, namely cuvette 100 except for the detection compartment 190F and what is stored in storage-compartment 139F. More specifically, the sample DNA probe is immobilized on portion "S" of membrane 194F, the positive control probe is immobilized on portion "+”, and the negative control probe is immobilized on portion "-”. Each portion of membrane 194F bearing such probes is preferably not in contact with the other portions.
  • the procedure in this case is to force amplified DNA via passageway 157F into detection compartment 190F, to flow over the entire surface of membrane 194F.
  • Appropriate heating causes amplified target DNA to hybridize specifically and thus attach to the probe in the "S” area, the ubiquitous DNA to attach to the probe in the "+” area, and preferably nothing to hybridize at the "-" area.
  • a wash solution is forced into compartment 190F, e.g. from 139F or elsewhere, followed by avidin-label, which then reacts with the biotinylated product now hybridized to either the amplified target DNA or the positive control DNA.
  • a wash solution is then added, followed by leuco dye and stop solution.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Clinical Laboratory Science (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Claims (37)

  1. Einwegküvette (10;10A; 10B; 100; 100C; 100D, 100E; 100F) für die Amplifikation und Detektion von Nukleinsäurematerial mit
    einer ersten Kammer (40; 40A; 40B; 126C),
    einer Vielzahl weiterer Kammern (26, 30, 32, 34, 36, 38, 42; 61, 26A, 30A, 38A; 26B, 30B, 32B, 34B, 36B, 38B, 42B; 126, 132, 134, 136, 138, 139, 140, 182; 132C, 134C, 136C, 138C; 126D, 132D, 134D, 138D; 126E, 136E, 138E, 182E, 250, 252, 254), von denen mindestens eine Kammer ein Material für die Amplifikation und Detektion von Nukleinsäurematerial enthält,
    Strömungsverbindungsmitteln (44, 48, 49, 50, 52, 54; 62, 44A, 48A, 49A, 50A, 52A, 54A; 54B; 144, 149, 150, 151, 152, 154, 155, 156, 157, 185; 144E, 151E, 157E, 262, 264, 266; 157F), die mindestens eine der weiteren Kammern derart mit der ersten Kammer (40; 40A; 40B; 126C) verbinden, daß das in mindestens der einen weiteren Kammer enthaltene Material in die erste Kammer (40; 40A; 40B; 126C) übertragbar ist, wenn das in dieser Kammer enthaltene Material mit Druck beaufschlagt wird,
    einer Detektionsstelle (39, 190; 190F), an der das Nukleinsäurematerial für die Detektion nach der Amplifikation immobilisierbar ist, und
    thermischen Transfermitteln, die eine aktive oder passive Cyclusbehandlung des Materials in der Küvette ermöglichen,
    dadurch gekennzeichnet, daß die erste Kammer (40; 40A; 40B; 126C) und die Detektionsstelle (39; 190; 190F) so verschlossen sind, daß keine Flüssigkeit zu außerhalb der Küvette liegenden Stellen strömt und während der Amplifikation und Detektion keine Aerosole abgebbar sind.
  2. Küvette nach Anspruch 1, dadurch gekennzeichnet, daß die thermischen Transfermittel eine aus einem Wärme übertragenden Material hergestellte Wandung der ersten Kammer (40; 40A; 40B; 126C) umfassen.
  3. Küvette nach Anspruch 2, dadurch gekennzeichnet, daß die Wärme übertragende Wandung eine Wärmeübertragungsstrecke von höchstens etwa 0,3 mm bildet und für einen Querschnittsbereich von 1 cm² einen thermischen Widerstand von höchstens etwa 5,0°C/W besitzt.
  4. Küvette nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, daß mindestens eine Wandung der mindestens einen weiteren Kammer so flexibel ist, daß die Kammer unter der Wirkung eines von außen auf sie ausgeübten Drucks zusammenpreßbar und das in dieser Kammer enthaltene Material zu der ersten Kammer (40; 40A; 40B; 126C) übertragbar ist.
  5. Küvette nach Anspruch 4, dadurch gekennzeichnet, daß die weiteren Kammern (26, 30, 32, 34, 36, 38, 42; 61, 26A, 30A, 38A; 26B, 30B, 32B, 34B, 36B, 38B, 42B) und ihre Strömungsverbindungsmittel (44, 48, 49, 50, 52, 54; 62, 44A, 48A, 49A, 50A, 52A, 54A; 54B) so angeordnet sind, daß das in jeder Kammer enthaltene Material in einer vorbestimmten Reihenfolge aus der Kammer herausdrückbar ist, indem die Küvette von außen linear an ihren Außenflächen Druck ausgesetzt wird.
  6. Küvette nach Anspruch 4 oder 5, dadurch gekennzeichnet, daß der Druck mittels einer sich über eine Außenfläche der Küvette bewegenden Rolle (60) ausübbar ist.
  7. Küvette nach einem der Ansprüche 4 bis 6, dadurch gekennzeichnet, daß eine der weiteren Kammern (61) Wasser enthält und mit allen anderen weiteren Kammern (26A, 30A, 38A) in Strömungsverbindung steht und daß diese eine Kammer so angeordnet ist, daß sie als erste dem Druck aussetzbar ist.
  8. Küvette nach einem der Ansprüche 1 bis 3, dadurch gekennzeichnet, daß eine der weiteren Kammern eine Reaktionskammer (26; 26A; 26B; 126; 126C; 126D; 126E) darstellt, in die das Nukleinsäurematerial einführbar ist.
  9. Küvette nach Anspruch 8, dadurch gekennzeichnet, daß in die Reaktionskammer (26; 26A; 26B; 126; 126C; 126D; 126E) noch nicht umgesetzte Amplifikationsmittel (28) vorab inkorporiert sind.
  10. Küvette nach Anspruch 9, dadurch gekennzeichnet, daß die noch nicht umgesetzten Amplifikationsmittel aus Polymerase-Enzym, Starter-Nukleinsäuren und Nukleotiden bestehen.
  11. Küvette nach Anspruch 9, dadurch gekennzeichnet, daß die noch nicht umgesetzten Amplifikationsmittel aus TAQ-Polymerase, Starter-Nukleinsäuren und Nukleotiden bestehen.
  12. Küvette nach einem der Ansprüche 1 bis 7, dadurch gekennzeichnet, daß eine Druckeinrichtung vorgesehen ist, die das in der mindestens einen weiteren Kammer enthaltene Material so mit Druck beaufschlagt, daß das Material in die erste Kammer übertragbar ist.
  13. Küvette nach Anspruch 12, dadurch gekennzeichnet, daß die Druckeinrichtung eine erste Kolben-Zylinder-Anordnung (113, 115) enthält, die sich in der mindestens einen weiteren Kammer befindet.
  14. Küvette nach Anspruch 12 oder 13, dadurch gekennzeichnet, daß die Druckeinrichtung eine zweite Kolben-Zylinder-Anordnung (182, 184; 182C, 184C; 182E, 184E) enthält, die mit der ersten Kammer (140; 126C) derart in Strömungsverbindung steht, daß beim Rückhub des zweiten Kolbens (184; 184C; 184E) in seinem Zylinder eine Druckentlastung in der ersten Kammer erfolgt.
  15. Küvette nach einem der Ansprüche 12 bis 14, dadurch gekennzeichnet, daß eine der weiteren Kammern eine Reaktionskammer (126D) ist, in die das Nukleinsäurematerial einführbar ist, daß die Küvette eine Extraktionskammer (200) enthält, die strömungsmäßig vor der Reaktionskammer (126D) angeordnet ist, und daß ein Filter (208) in der von der Extraktionskammer (200) zur Reaktionskammer (126D) verlaufenden Strömungsbahn angeordnet ist, wobei in der Extraktionskammer (200) zumindest aus Blutzellen DNS abtrennbar ist und durch das Filter (208) Zellfragmente von der DNS abtrennbar sind, so daß nur die DNS in die Reaktionskammer (126D) gelangt.
  16. Küvette nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, daß die Detektionsstelle (39; 190; 190F) eine Sonde umfaßt, die einem DNS-Material komplementäres genetisches Material enthält und deshalb bei geeigneter Erhitzung mit dem DNS-Material hybridisiert.
  17. Küvette nach Anspruch 16, dadurch gekennzeichnet, daß die Detektionsstelle außerdem eine Positivkontroll-Sonde umfaßt, die einer immer in einer Blutprobe vorhandenen amplifizierten DNS komplementär ist.
  18. Küvette nach Anspruch 17, dadurch gekennzeichnet, daß das genetische Material der Positivkontroll-Sonde Beta-Globin komplementär ist.
  19. Küvette nach Anspruch 17 oder 18, dadurch gekennzeichnet, daß die Positivkontroll-Sonde auf einem Abschnitt der Detektionsstelle in Abwesenheit von amplifizierter DNS immobilisiert ist.
  20. Küvette nach einem der Ansprüche 16 bis 19, dadurch gekennzeichnet, daß die Detektionsstelle außerdem eine Negativkontroll-Sonde umfaßt, die genetisches Material enthält, das keiner DNS komplementär ist, deren Vorhandensein nach der Amplifikation einer Blutprobe erwartet wird.
  21. Küvette nach Anspruch 20, dadurch gekennzeichnet, daß die Negativkontroll-Sonde auf einem Teil der Detektionsstelle in Abwesenheit von amplifizierter DNS immobilisiert ist.
  22. Küvette nach Anspruch 20 oder 21, dadurch gekennzeichnet, daß die Positivkontroll-Sonde und die Negativkontroll-Sonde in Abwesenheit von amplifizierter DNS auf einem Teil der Detektionsstelle immobilisiert sind, wobei die immobilisierten Abschnitte jeweils im wesentlichen von der anderen Kontrollsonde frei sind.
  23. Küvette nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, daß die Dektionsstelle (39) ein Trägerblatt (41) aufweist, auf dem eine Vielzahl von Erhebungen (43, 43' 43'', 43''') angeordnet sind, von denen jede aus einem Polymerkügelchen besteht, an das eine DNS-Sonde gebunden ist.
  24. Küvette nach einem der Ansprüche 1 bis 22, dadurch gekennzeichnet, daß die Detektionsstelle (39) ein Trägerblatt (41) umfaßt, auf dem eine Vielzahl von Erhebungen (43, 43', 43''; 43''') angeordnet ist, von denen jede aus einem Polymerkügelchen besteht, an das Avidin gebunden ist.
  25. Küvette nach einem der Ansprüche 16 bis 22, dadurch gekennzeichnet, daß sich die Detektionsstelle in der ersten Kammer (126C) befindet und das Material zum Detektieren des Nukleinsäurematerials ein Kügelchen enthält, das ein magnetisierbares Material umfaßt.
  26. Gerät zur DNS-Amplifikation und -Detektion mit einer Küvette nach einem der vorhergehenden Ansprüche.
  27. Gerät zur DNS-Amplifikation und -Detektion mit einer Küvette, die
    (i) eine Vielzahl von Kammern sowie Mittel zum Verbinden jeder dieser Kammern mit mindestens einer anderen Kammer enthält, wobei die Kammern a) mindestens eine Reaktionskammer zur Amplifikation von DNS-Strängen, (b) mindestens eine eine Detektionsstelle enthaltende Detektionskammer zur Detektion von amplifizierter DNS und c) Mittel zum Zuführen eines Detektionsmaterials zu amplifizierten DNS-Strängen umfassen,
    (ii) Mittel aufweist, die eine aktive oder passive Cyclusbehandlung des Inhalts der Reaktionskammer in einem Temperaturbereich von etwa 30°C bis etwa 95°C erlauben, und
    (iii) Flüssigkeitseinlaßmittel besitzt, die nur mit der mindestens einen Reaktionskammer verbunden sind und durch die eine DNS-Probe zur Amplifikation in die Reaktionskammer injizierbar ist,
    dadurch gekennzeichnet, daß die Küvette außerdem
    (iv) Verschlußmittel enthält, die verhindern, daß nach der Injektion der DNS-Probe DNS aus der Küvette herausgelangt, und
    daß das Gerät Mittel aufweist, durch die mindestens das Detektionsmaterial und ein DNS-Strang in die Detektionskammer und auf die Detektionsstelle bewegbar sind, so daß
    nach Injektion einer DNS-Probe in die Kammern und Schließen der Einlaßöffnung der flüssige Inhalt der Kammern während der gesamten Amplifikations- und Detektionsreaktion nicht mit der Bedienungsperson und der Umgebung in Berührung gelangt.
  28. Verfahren zur Amplifikation und Detektion von Nukleinsäurematerial in einer geschlossenen Küvette, dadurch gekennzeichnet, daß in einer Reihe von Arbeitsschritten
    a) eine Probe eines Nukleinsäurematerials in eine Küvette injiziert wird, die eine Vielzahl von Kammern enthält, einschließlich einer Reaktionskammer, in der Amplifikations-Reagenzien enthalten sind, und einer Speicherkammer, die in Verbindung mit einem Detektionsmaterial verwendbar ist, wobei mindestens eine der Kammern eine Detektionsstelle enthält und Mittel vorgesehen sind, die die Kammern zur Übertragung der Flüssigkeiten miteinander verbinden,
    b) die das Nukleinsäurematerial enthaltenden Bereiche der Küvette dauerhaft verschlossen werden, so daß die gesamte Nukleinsäure in der Küvette eingeschlossen ist,
    c) das Nukleinsäurematerial amplifiziert wird, indem die Küvette thermischen Cyclen unterworfen wird, die so vorgewählt werden, daß die Reagenzien ihre Wirkung entfalten,
    d) das amplifizierte Nukleinsäurematerial in flüssiger Form aus der Reaktionskammer zu der Detektionstelle übertragen wird,
    e) Detektionsmaterial in flüssiger Form zu der Detektionsstelle übertragen wird und
    f) an der Detektionsstelle mittels des Detektionsmaterials das amplifizierte Nukleinsäurematerial nachgewiesen wird, wobei das Nukleinsäurematerial in der Küvette eingeschlossen bleibt.
  29. Verfahren nach Anspruch 28, dadurch gekennzeichnet, daß in Arbeitsschritt c) die Wärmeübertragung über eine Wärmeübertragungswandung der Reaktionskammer in die Kammer hinein und aus der Kammer heraus erfolgt und daß die Wärmeübertragungswandung mindestens ein wärmeleitfähiges Material aufweist.
  30. Verfahren nach Anspruch 29, dadurch gekennzeichnet, daß die Wärmeübertragungswandung eine Übertragungsstrecke von nicht mehr als 0,3 mm bildet und für einen Querschnittsbereich von 1 cm² einen thermischen Widerstand von nicht mehr als 5,0°C/W besitzt.
  31. Verfahren nach einem der Ansprüche 28 bis 30, dadurch gekennzeichnet, daß die Küvette in einer der mit der Reaktionskammer in Strömungsverbindung stehenden Kammern eine erste Kolben- und Zylinderanordnung besitzt, und beim Vorwärtshub des Kolbens in dieser Kammer der Druck in der Reaktionskammer steigt, und in einer anderen der Kammern, die mit der Detektionsstelle in Strömungsverbindung steht, eine zweite Kolben- und Zylinderanordnung vorgesehen ist, durch deren zweiten Kolben beim Rückhub im Zylinder eine Druckentlastung an der Detektionsstelle erfolgt, und daß in Arbeitsschritt d) der erste Kolben vorwärtsbewegt und der zweite Kolben zurückbewegt wird.
  32. Verfahren nach einem der Ansprüche 28 bis 30, dadurch gekennzeichnet, daß mindestens eine Wandung der Kammern jeweils so flexibel ist, daß die Kammern durch Druck von außen zusammendrückbar und Flüssigkeit aus den Kammern übertragbar ist, und daS in Arbeitschritt d) die flexiblen Wandungen der Kammern in einer vorbestimmten Reihenfolge von außen mit Druck beaufschlagt werden.
  33. Verfahren nach einem der Ansprüche 28 bis 30, dadurch gekennzeichnet, daß die Detektionsreagenzien ein aus magnetisierbarem Material bestehendes Kügelchen enthalten, daß in den Arbeitschritten d) bis f) die Kügelchen in die Reaktionskammer übertragen und an das amplifizierte Nukleinsäurematerial angebunden werden, das Detektionsmaterial an das amplifizierte Material angebunden wird und nicht angebundenes Detektionsmaterial durch Waschen in Gegenwart eines Magnetfeldes entfernt wird, das die Kügelchen und das angebundene Detektionsmaterial in der Reaktionskammer zurückhält.
  34. Verfahren nach einem der Ansprüche 28 bis 30, dadurch gekennzeichnet, daß die Arbeitschritte d) und e) nacheinander durchgeführt werden, indem zuerst die Reaktionskammer und anschließend eine Speicherkammer mit Druck beaufschlagt wird.
  35. Verfahren nach einem der Ansprüche 28 bis 30, dadurch gekennzeichnet, daß in den Arbeitschritten d) und e) die Speicherkammer und die Reaktionskammer gleichzeitig mit Druck beaufschlagt werden und die Strömung des Detektionsmaterials aufgehalten wird, bis amplifiziertes Nukleinsäurematerial übertragen worden ist.
  36. Verfahren nach einem der Ansprüche 28 bis 30, daß vor Arbeitsschritt e) Detektionsmaterial, das in getrockneter Form in einer Speicherkammer vorgesehen ist, rekonstituiert wird, indem zuvor inkorporiertes Wasser aus einer Speicherkammer zu dem getrockneten Material geleitet wird.
  37. Verfahren nach einem der Ansprüche 28 bis 31, dadurch gekennzeichnet, daß in Arbeitsschritt a) mindestens Blutzellen und wahlweise DNS-Extraktionsmittel in eine vorbestimmte Kammer zur Herstellung einer Lösung injiziert werden und
    vor Arbeitsschritt c)
    (i) DNS aus den in der vorbestimmten Kammer enthaltenen Zellen extrahiert und
    (ii) nach einer geeigneten Inkubationszeit die Lösung aus extrahierter DNS und Zellfragmenten durch ein zwischen der vorbestimmten Kammer und der Reaktionskammer befindliches Filter geleitet wird, wobei das Filter so gewählt ist, daß Zellfragmente zurückgehalten werden, jedoch DNS durchgelassen wird.
EP90301061A 1989-02-03 1990-02-01 Küvette für eine Polymerase-Reaktion und ihre Verwendung Expired - Lifetime EP0381501B1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30673589A 1989-02-03 1989-02-03
US306735 1989-02-03
US33992389A 1989-04-17 1989-04-17
US339923 1989-04-17

Publications (3)

Publication Number Publication Date
EP0381501A2 EP0381501A2 (de) 1990-08-08
EP0381501A3 EP0381501A3 (de) 1991-06-05
EP0381501B1 true EP0381501B1 (de) 1994-06-08

Family

ID=26975330

Family Applications (1)

Application Number Title Priority Date Filing Date
EP90301061A Expired - Lifetime EP0381501B1 (de) 1989-02-03 1990-02-01 Küvette für eine Polymerase-Reaktion und ihre Verwendung

Country Status (7)

Country Link
EP (1) EP0381501B1 (de)
JP (1) JP2536945B2 (de)
KR (2) KR0161276B1 (de)
CA (1) CA1338505C (de)
DE (1) DE69009510T2 (de)
DK (1) DK0381501T3 (de)
FI (1) FI94360C (de)

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991012342A1 (en) * 1990-02-16 1991-08-22 F. Hoffmann-La Roche Ag Improvements in the specificity and convenience of the polymerase chain reaction
EP0478047A1 (de) * 1990-09-17 1992-04-01 Johnson & Johnson Clinical Diagnostics, Inc. Testvorrichtungen
FR2669347A1 (fr) * 1990-11-15 1992-05-22 Inst Nat Sante Rech Med Procede permettant d'effectuer au moins deux reactions successives, en evitant les risques de contamination, notamment applicable aux techniques d'amplification de l'adn ou de l'arn.
US5133938A (en) * 1990-10-25 1992-07-28 Eastman Kodak Company Lockable valve mechanism for sample pouch
FR2672301A1 (fr) * 1991-02-01 1992-08-07 Larzul Daniel Procede et dispositif pour amplifier le nombre d'une sequence definie d'acide nucleique dans un echantillon biologique.
FR2674253A1 (fr) * 1991-03-19 1992-09-25 Diagnostics Pasteur Composition lyophilisee pour la multiplication de sequences d'acides nucleiques.
US5154888A (en) * 1990-10-25 1992-10-13 Eastman Kodak Company Automatic sealing closure means for closing off a passage in a flexible cuvette
EP0504772A3 (en) * 1991-03-18 1993-01-27 Paradigm Biotechnologies Partnership Analytical apparatus
EP0550090A1 (de) * 1991-12-19 1993-07-07 Johnson & Johnson Clinical Diagnostics, Inc. Verfahren zur Verarbeitung von flexiblen Reaktionsküvetten
WO1993015222A1 (fr) * 1992-01-29 1993-08-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Procede pour eviter les risques de contamination, notamment applicable aux techniques d'amplification de l'adn ou de l'arn
WO1993016194A1 (de) * 1992-02-05 1993-08-19 Diagen Institut Für Molekular-Biologische Diagnostik Gmbh Verfahren zur bestimmung von in vitro amplifizierten nukleinsäuren
WO1993017328A1 (en) * 1992-02-20 1993-09-02 Drew Scientific Limited Liquid chromatography apparatus
US5258314A (en) * 1991-03-18 1993-11-02 Paradigm Biotechnologies Partnership Microprocessor-based biomedical monitoring apparatus and method
US5288463A (en) * 1992-10-23 1994-02-22 Eastman Kodak Company Positive flow control in an unvented container
US5290518A (en) * 1992-08-17 1994-03-01 Eastman Kodak Company Flexible extraction device with burstable sidewall
US5364591A (en) * 1992-06-01 1994-11-15 Eastman Kodak Company Device for moving a target-bearing solid through a liquid for detection while being contained
US5380489A (en) * 1992-02-18 1995-01-10 Eastman Kodak Company Element and method for nucleic acid amplification and detection using adhered probes
US5415839A (en) * 1993-10-21 1995-05-16 Abbott Laboratories Apparatus and method for amplifying and detecting target nucleic acids
US5422271A (en) * 1992-11-20 1995-06-06 Eastman Kodak Company Nucleic acid material amplification and detection without washing
US5425917A (en) * 1992-11-09 1995-06-20 Schmid; Peter Apparatus for attaching a labeled probe and/or antibody to macromolecules
EP0687502A2 (de) 1994-06-15 1995-12-20 Roche Diagnostics GmbH Vorrichtung zur Behandlung von Nukelinsäuren aus einer Probe
US5565339A (en) * 1992-10-08 1996-10-15 Hoffmann-La Roche Inc. Compositions and methods for inhibiting dimerization of primers during storage of polymerase chain reaction reagents
US5567617A (en) * 1994-01-06 1996-10-22 Johnson & Johnson Clinical Diagnostics, Inc. Apparatus for heating a fluid-carrying compartment of reaction cuvette
US5605796A (en) * 1994-07-19 1997-02-25 Behringwerke Ag Method for preventing amplification of nucleic acid contaminants in amplification mixtures using nuclease-receptor conjugates
US5639423A (en) * 1992-08-31 1997-06-17 The Regents Of The University Of Calfornia Microfabricated reactor
US5645801A (en) * 1993-10-21 1997-07-08 Abbott Laboratories Device and method for amplifying and detecting target nucleic acids
US5714380A (en) * 1986-10-23 1998-02-03 Amoco Corporation Closed vessel for isolating target molecules and for performing amplification
US5725831A (en) * 1994-03-14 1998-03-10 Becton Dickinson And Company Nucleic acid amplification apparatus
US5783148A (en) * 1994-03-14 1998-07-21 Becton Dickinson And Company Nucleic acid amplification method and apparatus
US5819842A (en) * 1991-12-05 1998-10-13 Potter; Derek Henry Method and apparatus for temperature control of multiple samples
US5888723A (en) * 1992-02-18 1999-03-30 Johnson & Johnson Clinical Diagnostics, Inc. Method for nucleic acid amplification and detection using adhered probes
US5916522A (en) * 1997-08-07 1999-06-29 Careside, Inc. Electrochemical analytical cartridge
US5919711A (en) * 1997-08-07 1999-07-06 Careside, Inc. Analytical cartridge
US5971158A (en) * 1996-06-14 1999-10-26 University Of Washington Absorption-enhanced differential extraction device
US6002475A (en) * 1998-01-28 1999-12-14 Careside, Inc. Spectrophotometric analytical cartridge
US6068978A (en) * 1993-10-21 2000-05-30 Abbott Laboratories Apparatus and method for transfer of a fluid sample
US6537501B1 (en) 1998-05-18 2003-03-25 University Of Washington Disposable hematology cartridge
US6541213B1 (en) 1996-03-29 2003-04-01 University Of Washington Microscale diffusion immunoassay
US6582963B1 (en) 1996-03-29 2003-06-24 University Of Washington Simultaneous analyte determination and reference balancing in reference T-sensor devices
US6743399B1 (en) 1999-10-08 2004-06-01 Micronics, Inc. Pumpless microfluidics
US6830729B1 (en) 1998-05-18 2004-12-14 University Of Washington Sample analysis instrument
US7297313B1 (en) 1991-08-31 2007-11-20 The Regents Of The University Of California Microfabricated reactor, process for manufacturing the reactor, and method of amplification
US7329496B2 (en) 1990-12-06 2008-02-12 Affymetrix, Inc. Sequencing of surface immobilized polymers utilizing microflourescence detection
US8101431B2 (en) 2004-02-27 2012-01-24 Board Of Regents, The University Of Texas System Integration of fluids and reagents into self-contained cartridges containing sensor elements and reagent delivery systems
US8797527B2 (en) 2011-08-24 2014-08-05 Abbott Point Of Care, Inc. Biologic fluid sample analysis cartridge
US9579651B2 (en) 2009-12-18 2017-02-28 Abbott Point Of Care, Inc. Biologic fluid analysis cartridge

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0693964A1 (de) * 1992-04-23 1996-01-31 Amoco Corporation Geschlossener behälter zur isolation von ziel-molekülen und zur verstärkung
DK0594259T3 (da) * 1992-10-23 1996-11-18 Johnson & Johnson Clin Diag Strømningsregulering i en lukket beholderindretning
TW313588B (de) * 1992-10-23 1997-08-21 Eastman Kodak Co
WO1994026414A1 (en) * 1993-05-17 1994-11-24 Syntex (U.S.A.) Inc. Reaction container for specific binding assays and method for its use
CA2222126A1 (en) * 1995-06-16 1997-01-03 Fred K. Forster Microfabricated differential extraction device and method
US5716852A (en) * 1996-03-29 1998-02-10 University Of Washington Microfabricated diffusion-based chemical sensor
US6454945B1 (en) 1995-06-16 2002-09-24 University Of Washington Microfabricated devices and methods
FR2760838B1 (fr) * 1997-03-13 1999-05-21 Corning Inc Circuit fluidique integre d'execution d'un processus de preparation ou d'analyse d'un echantillon de matiere fluide, son procede de fabrication et appareil d'exploitation de ce circuit
FR2762910B1 (fr) * 1997-05-05 1999-06-11 Bio Merieux Dispositif de transfert d'un liquide
JP2001518624A (ja) 1997-09-26 2001-10-16 ユニバーシティ・オブ・ワシントン 同時の粒子分離および化学反応
US6723290B1 (en) 1998-03-07 2004-04-20 Levine Robert A Container for holding biologic fluid for analysis
EP1614473A3 (de) 1998-05-01 2007-03-14 Gen-Probe Incorporated Mehrfachringaufbau zum liefern von Proben an Reaktionsbehälter in einer automatischen Analysevorrichtung
US6780617B2 (en) 2000-12-29 2004-08-24 Chen & Chen, Llc Sample processing device and method
DE19903704C1 (de) * 1999-01-30 2000-11-30 Fresenius Medical Care De Gmbh Aufnahmeeinheit für Lösungen, insbesondere Lösungen zur Kalibrierung von Sensoren zur Messung physiologisch relevanter Parameter
ES2272289T5 (es) * 1999-05-28 2011-10-21 Cepheid Cartucho para realizar una reacción química.
FR2806009B1 (fr) * 2000-03-07 2002-05-31 Bio Merieux Procede de mise en oeuvre d'une carte d'analyse
KR100401389B1 (ko) * 2000-10-27 2003-10-17 김희태 핵산 검출 방법, 이를 위한 키트 및 이 키트를 구동시키기위한 구동장치
EP1390466A4 (de) * 2001-04-26 2010-07-28 Pressure Biosciences Inc Mehrkammervorrichtung und ihre verwendung zur bearbeitung biologischer proben
CA2460192C (en) 2001-09-11 2011-04-19 Iquum, Inc. Sample vessels
DE10258840A1 (de) 2002-01-28 2003-08-07 Eppendorf Ag Stapelanordnung von Reaktionsgefäßen
GB0227765D0 (en) * 2002-11-28 2003-01-08 Secr Defence Apparatus for processing a fluid sample
CA3171720C (en) 2002-12-26 2024-01-09 Meso Scale Technologies, Llc. Methods for conducting electrochemiluminescence measurements
CN1767897B (zh) * 2003-02-05 2011-03-02 伊库姆公司 试样处理细管
US7854897B2 (en) 2003-05-12 2010-12-21 Yokogawa Electric Corporation Chemical reaction cartridge, its fabrication method, and a chemical reaction cartridge drive system
DE10330804A1 (de) * 2003-07-08 2005-04-28 Fresenius Medical Care De Gmbh Einwegkassette
JP4208820B2 (ja) 2003-11-28 2009-01-14 株式会社東芝 核酸検出カセット
GB2416030B (en) * 2004-01-28 2008-07-23 Norchip As A diagnostic system for carrying out a nucleic acid sequence amplification and detection process
JP4127679B2 (ja) 2004-03-18 2008-07-30 株式会社東芝 核酸検出カセット及び核酸検出装置
WO2006036592A1 (en) 2004-09-23 2006-04-06 University Of Washington Microscale diffusion immunoassay utilizing multivalent reactants
DE102004051573B4 (de) * 2004-10-22 2007-03-15 Yokogawa Electric Corporation, Musashino Verfahren zur Behandlung einer Abfallflüssigkeit in Chemischen Reaktions-Patronen und chemische Reaktions-Patrone, in der das Verfahren angewendet wird
AU2005299590B2 (en) * 2004-10-27 2010-09-16 Cepheid Closed-system multi-stage nucleic acid amplification reactions
CN100462710C (zh) * 2004-11-09 2009-02-18 横河电机株式会社 在盒中处理废液的方法及应用此方法的化学反应盒
US7897337B2 (en) 2005-03-10 2011-03-01 Gen-Probe Incorporated Method for performing multi-formatted assays
ES2752000T3 (es) 2005-05-09 2020-04-02 Biofire Diagnostics Llc Análisis biológico autónomo
EP2508867A1 (de) * 2005-06-24 2012-10-10 Board Of Regents, The University Of Texas System Systeme und Verfahren einschliesslich in sich geschlossener Kassetten mit Nachweissystemen und Flüssigkeitszufuhrsystemen
JP4692200B2 (ja) * 2005-10-06 2011-06-01 横河電機株式会社 化学処理用カートリッジおよびその使用方法
DE102006010958A1 (de) * 2006-03-06 2007-09-13 Directif Gmbh Verfahren zur Durchführung einer Reaktion zur Vervielfältigung einer Nukleinsäure
US9839909B2 (en) 2006-07-28 2017-12-12 Diagnostics For The Real World, Ltd. Device, system and method for processing a sample
US9102911B2 (en) 2009-05-15 2015-08-11 Biofire Diagnostics, Llc High density self-contained biological analysis
JP2008263959A (ja) 2007-03-23 2008-11-06 Toshiba Corp 核酸検出カセット及び核酸検出装置
EP2089159B1 (de) * 2007-05-03 2013-01-23 Clondiag GmbH Tests
GB2456079B (en) * 2007-08-17 2010-07-14 Diagnostics For The Real World Device, system and method for processing a sample
EP2042237A1 (de) * 2007-09-28 2009-04-01 Koninklijke Philips Electronics N.V. Reaktorsystem mit Reaktionskammern und Verfahren zum Füllen und Entleeren der Reaktionskammern
US7850917B2 (en) * 2008-03-11 2010-12-14 Ortho-Clinical Diagnostics, Inc. Particle agglutination in a tip
CA2638458A1 (en) 2008-07-31 2010-01-31 Spartan Bioscience Inc. Thermal recycling by positioning relative to fixed-temperature source
SG175699A1 (en) 2009-03-19 2011-12-29 Kaneka Corp Method, kit and device for detecting nucleic acid
US9199233B2 (en) 2010-03-31 2015-12-01 Abbott Point Of Care, Inc. Biologic fluid analysis cartridge with deflecting top panel
US9046507B2 (en) 2010-07-29 2015-06-02 Gen-Probe Incorporated Method, system and apparatus for incorporating capacitive proximity sensing in an automated fluid transfer procedure
CN103119178B (zh) * 2010-09-22 2017-05-17 株式会社钟化 核酸的检测方法以及装置、试剂盒
EP2624955A1 (de) * 2010-10-07 2013-08-14 BOEHRINGER INGELHEIM microParts GmbH Mikrofluidische plattform
CN103282123B (zh) 2010-12-30 2015-05-06 艾博特健康公司 带有样品处理区和分析室区的生物液体分析卡式盒
EP2678664B1 (de) 2011-02-24 2019-08-07 Gen-Probe Incorporated Systeme und verfahren zur unterscheidung optischer signale mit verschiedenen modulationsfrequenzen bei einem optischen signaldetektor
CA3206928A1 (en) 2012-11-07 2014-05-15 Yale University Assessing risk of reading and language impairment
US10391498B2 (en) 2015-12-11 2019-08-27 Spartan Bioscience Inc. Systems and methods for nucleic acid amplification
JP2018174826A (ja) * 2017-04-14 2018-11-15 キヤノンメディカルシステムズ株式会社 核酸調製器具
JP6863074B2 (ja) * 2017-05-24 2021-04-21 住友ゴム工業株式会社 マイクロ流路チップ
CN110892247B (zh) 2017-08-17 2023-08-25 雅培医护站股份有限公司 用于执行光学和电化学测定的设备、系统和方法
WO2019035077A1 (en) 2017-08-17 2019-02-21 Abbott Point Of Care Inc. DEVICES, SYSTEMS AND METHODS FOR PERFORMING OPTICAL ASSAYS
CN114025880B (zh) * 2019-04-26 2023-10-10 斯蒂拉科技公司 聚合酶链反应设备及其用于压力控制释放流体的方法
FR3102558B1 (fr) * 2019-10-29 2024-11-29 Biomerieux Sa Système de dilution dans un dispositif et procédé de fabrication du dispositif
CN113897283A (zh) * 2021-05-18 2022-01-07 成都万众壹芯生物科技有限公司 一种微流控核酸检测试剂盒及检测装置
CN114056769A (zh) * 2021-11-09 2022-02-18 杭州遂真生物技术有限公司 一种基于移动柱塞的气动一体式pcr检测试剂盒及其检测方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4585623A (en) * 1984-02-27 1986-04-29 Allelix Inc. Device for performing quantitative chemical and immunochemical assays
CA1339653C (en) * 1986-02-25 1998-02-03 Larry J. Johnson Appartus and method for performing automated amplification of nucleic acid sequences and assays using heating and cooling steps
CA1284931C (en) * 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
US4690801A (en) * 1986-06-03 1987-09-01 Allelix Inc. Device for performing enzyme immunoassays
US4918025A (en) * 1987-03-03 1990-04-17 Pb Diagnostic Systems, Inc. Self contained immunoassay element
FR2612295B1 (fr) * 1987-03-11 1989-07-13 Abensour David Micro-analyseur automatique par colorimetrie ou bioluminescence
US4902624A (en) * 1987-11-23 1990-02-20 Eastman Kodak Company Temperature cycling cuvette

Cited By (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714380A (en) * 1986-10-23 1998-02-03 Amoco Corporation Closed vessel for isolating target molecules and for performing amplification
WO1991012342A1 (en) * 1990-02-16 1991-08-22 F. Hoffmann-La Roche Ag Improvements in the specificity and convenience of the polymerase chain reaction
US5173260A (en) * 1990-09-17 1992-12-22 Eastman Kodak Company Beads fused to a test device support
EP0478047A1 (de) * 1990-09-17 1992-04-01 Johnson & Johnson Clinical Diagnostics, Inc. Testvorrichtungen
EP0482713A3 (en) * 1990-10-25 1992-11-25 Eastman Kodak Company Reaction vessels
US5133938A (en) * 1990-10-25 1992-07-28 Eastman Kodak Company Lockable valve mechanism for sample pouch
US5154888A (en) * 1990-10-25 1992-10-13 Eastman Kodak Company Automatic sealing closure means for closing off a passage in a flexible cuvette
FR2669347A1 (fr) * 1990-11-15 1992-05-22 Inst Nat Sante Rech Med Procede permettant d'effectuer au moins deux reactions successives, en evitant les risques de contamination, notamment applicable aux techniques d'amplification de l'adn ou de l'arn.
US7329496B2 (en) 1990-12-06 2008-02-12 Affymetrix, Inc. Sequencing of surface immobilized polymers utilizing microflourescence detection
US7459275B2 (en) 1990-12-06 2008-12-02 Affymetrix, Inc. Sequencing of surface immobilized polymers utilizing microfluorescence detection
FR2672301A1 (fr) * 1991-02-01 1992-08-07 Larzul Daniel Procede et dispositif pour amplifier le nombre d'une sequence definie d'acide nucleique dans un echantillon biologique.
EP0504772A3 (en) * 1991-03-18 1993-01-27 Paradigm Biotechnologies Partnership Analytical apparatus
US5258314A (en) * 1991-03-18 1993-11-02 Paradigm Biotechnologies Partnership Microprocessor-based biomedical monitoring apparatus and method
FR2674253A1 (fr) * 1991-03-19 1992-09-25 Diagnostics Pasteur Composition lyophilisee pour la multiplication de sequences d'acides nucleiques.
US7297313B1 (en) 1991-08-31 2007-11-20 The Regents Of The University Of California Microfabricated reactor, process for manufacturing the reactor, and method of amplification
US5819842A (en) * 1991-12-05 1998-10-13 Potter; Derek Henry Method and apparatus for temperature control of multiple samples
EP0550090A1 (de) * 1991-12-19 1993-07-07 Johnson & Johnson Clinical Diagnostics, Inc. Verfahren zur Verarbeitung von flexiblen Reaktionsküvetten
WO1993015222A1 (fr) * 1992-01-29 1993-08-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Procede pour eviter les risques de contamination, notamment applicable aux techniques d'amplification de l'adn ou de l'arn
WO1993016194A1 (de) * 1992-02-05 1993-08-19 Diagen Institut Für Molekular-Biologische Diagnostik Gmbh Verfahren zur bestimmung von in vitro amplifizierten nukleinsäuren
US5871908A (en) * 1992-02-05 1999-02-16 Evotec Biosystems Gmbh Process for the determination of in vitro amplified nucleic acids
US5380489A (en) * 1992-02-18 1995-01-10 Eastman Kodak Company Element and method for nucleic acid amplification and detection using adhered probes
US5888723A (en) * 1992-02-18 1999-03-30 Johnson & Johnson Clinical Diagnostics, Inc. Method for nucleic acid amplification and detection using adhered probes
WO1993017328A1 (en) * 1992-02-20 1993-09-02 Drew Scientific Limited Liquid chromatography apparatus
US5364591A (en) * 1992-06-01 1994-11-15 Eastman Kodak Company Device for moving a target-bearing solid through a liquid for detection while being contained
US5290518A (en) * 1992-08-17 1994-03-01 Eastman Kodak Company Flexible extraction device with burstable sidewall
US5674742A (en) * 1992-08-31 1997-10-07 The Regents Of The University Of California Microfabricated reactor
US5639423A (en) * 1992-08-31 1997-06-17 The Regents Of The University Of Calfornia Microfabricated reactor
US5646039A (en) * 1992-08-31 1997-07-08 The Regents Of The University Of California Microfabricated reactor
US7169601B1 (en) 1992-08-31 2007-01-30 The Regents Of The University Of California Microfabricated reactor
US7935312B2 (en) 1992-08-31 2011-05-03 Regents Of The University Of California Microfabricated reactor, process for manufacturing the reactor, and method of amplification
US5565339A (en) * 1992-10-08 1996-10-15 Hoffmann-La Roche Inc. Compositions and methods for inhibiting dimerization of primers during storage of polymerase chain reaction reagents
US5288463A (en) * 1992-10-23 1994-02-22 Eastman Kodak Company Positive flow control in an unvented container
US5425917A (en) * 1992-11-09 1995-06-20 Schmid; Peter Apparatus for attaching a labeled probe and/or antibody to macromolecules
US5422271A (en) * 1992-11-20 1995-06-06 Eastman Kodak Company Nucleic acid material amplification and detection without washing
US6068978A (en) * 1993-10-21 2000-05-30 Abbott Laboratories Apparatus and method for transfer of a fluid sample
US5415839A (en) * 1993-10-21 1995-05-16 Abbott Laboratories Apparatus and method for amplifying and detecting target nucleic acids
US5645801A (en) * 1993-10-21 1997-07-08 Abbott Laboratories Device and method for amplifying and detecting target nucleic acids
US5567617A (en) * 1994-01-06 1996-10-22 Johnson & Johnson Clinical Diagnostics, Inc. Apparatus for heating a fluid-carrying compartment of reaction cuvette
US5725831A (en) * 1994-03-14 1998-03-10 Becton Dickinson And Company Nucleic acid amplification apparatus
US5783148A (en) * 1994-03-14 1998-07-21 Becton Dickinson And Company Nucleic acid amplification method and apparatus
EP0687502A2 (de) 1994-06-15 1995-12-20 Roche Diagnostics GmbH Vorrichtung zur Behandlung von Nukelinsäuren aus einer Probe
US5746978A (en) * 1994-06-15 1998-05-05 Boehringer Mannheim Gmbh Device for treating nucleic acids from a sample
US5605796A (en) * 1994-07-19 1997-02-25 Behringwerke Ag Method for preventing amplification of nucleic acid contaminants in amplification mixtures using nuclease-receptor conjugates
US6541213B1 (en) 1996-03-29 2003-04-01 University Of Washington Microscale diffusion immunoassay
US6582963B1 (en) 1996-03-29 2003-06-24 University Of Washington Simultaneous analyte determination and reference balancing in reference T-sensor devices
US6695147B1 (en) 1996-06-14 2004-02-24 University Of Washington Absorption-enhanced differential extraction device
US5971158A (en) * 1996-06-14 1999-10-26 University Of Washington Absorption-enhanced differential extraction device
US5916522A (en) * 1997-08-07 1999-06-29 Careside, Inc. Electrochemical analytical cartridge
US5919711A (en) * 1997-08-07 1999-07-06 Careside, Inc. Analytical cartridge
US6033914A (en) * 1997-08-07 2000-03-07 Careside, Inc. Electrochemical analytical cartridge
US6002475A (en) * 1998-01-28 1999-12-14 Careside, Inc. Spectrophotometric analytical cartridge
US7226562B2 (en) 1998-05-18 2007-06-05 University Of Washington Liquid analysis cartridge
US6852284B1 (en) 1998-05-18 2005-02-08 University Of Washington Liquid analysis cartridge
US6576194B1 (en) 1998-05-18 2003-06-10 University Of Washington Sheath flow assembly
US6656431B2 (en) 1998-05-18 2003-12-02 University Of Washington Sample analysis instrument
US6830729B1 (en) 1998-05-18 2004-12-14 University Of Washington Sample analysis instrument
US6537501B1 (en) 1998-05-18 2003-03-25 University Of Washington Disposable hematology cartridge
US6712925B1 (en) 1998-05-18 2004-03-30 University Of Washington Method of making a liquid analysis cartridge
US6743399B1 (en) 1999-10-08 2004-06-01 Micronics, Inc. Pumpless microfluidics
US8101431B2 (en) 2004-02-27 2012-01-24 Board Of Regents, The University Of Texas System Integration of fluids and reagents into self-contained cartridges containing sensor elements and reagent delivery systems
US9579651B2 (en) 2009-12-18 2017-02-28 Abbott Point Of Care, Inc. Biologic fluid analysis cartridge
US8797527B2 (en) 2011-08-24 2014-08-05 Abbott Point Of Care, Inc. Biologic fluid sample analysis cartridge

Also Published As

Publication number Publication date
EP0381501A2 (de) 1990-08-08
FI900535A0 (fi) 1990-02-02
FI94360C (fi) 1995-08-25
KR900013084A (ko) 1990-09-03
KR0161276B1 (ko) 1998-11-16
EP0381501A3 (de) 1991-06-05
DE69009510D1 (de) 1994-07-14
JP2536945B2 (ja) 1996-09-25
DE69009510T2 (de) 1995-01-05
CA1338505C (en) 1996-08-06
KR0161352B1 (ko) 1999-10-01
DK0381501T3 (da) 1994-07-04
FI94360B (fi) 1995-05-15
JPH037571A (ja) 1991-01-14

Similar Documents

Publication Publication Date Title
EP0381501B1 (de) Küvette für eine Polymerase-Reaktion und ihre Verwendung
US5229297A (en) Containment cuvette for PCR and method of use
US6645758B1 (en) Containment cuvette for PCR and method of use
CA2892980C (en) Device and method for carrying out an assay to detect a nucleic acid in a sample
AU2010311138B2 (en) Device and apparatus
EP0318255B1 (de) Küvette
US20130171045A1 (en) Sample Withdrawal and Dispensing Device
US6426230B1 (en) Disposable diagnostic device and method
EP0478047B1 (de) Testvorrichtungen
EP0752105B1 (de) Molekularanalysator und verfahren zu seiner verwendung
US6372484B1 (en) Apparatus for integrated polymerase chain reaction and capillary electrophoresis
US20080003145A1 (en) Sample Distribution Devices and Methods
US20050196779A1 (en) Self-contained microfluidic biochip and apparatus
WO1994026414A1 (en) Reaction container for specific binding assays and method for its use
CN105543084A (zh) 分析系统
EP3381562A1 (de) Microspotting-vorrichtung
PL185992B1 (pl) Sposób przechowywania i dozowania odczynników biochemicznych w zespołach pojemników oraz zespół pojemników do przechowywania i dozowania odczynników biochemicznych
IE63501B1 (en) Containment cuvette for pcr and method of use
JPH09224644A (ja) Ｐｃｒ装置
JPH04212036A (ja) 化学反応パック及びその使用方法
GB2418489A (en) Sample withdrawal and dispensing device

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): BE CH DE DK FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19901213

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): BE CH DE DK FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19930305

RIN1 Information on inventor provided before grant (corrected)

Inventor name: FINDLAY, JOHN B., C/O EASTMAN KODAK CO.,

Inventor name: DONISH, WILLIAM H., C/O EASTMAN KODAK CO.

Inventor name: HINCKLEY, CHARLES C., C/O EASTMAN KODAK CO.

Inventor name: WELLMAN, JEFFREY A., C/O EASTMAN KODAK CO.

Inventor name: SEABERG, LEONARD J., C/O EASTMAN KODAK CO.

Inventor name: SCHNIPELSKY, PAUL N., C/O EASTMAN KODAK CO.

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

ITF It: translation for a ep patent filed
AK Designated contracting states

Kind code of ref document: B1

Designated state(s): BE CH DE DK FR GB IT LI LU NL SE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REF Corresponds to:

Ref document number: 69009510

Country of ref document: DE

Date of ref document: 19940714

ET Fr: translation filed
EAL Se: european patent in force in sweden

Ref document number: 90301061.9

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 19950201

BECN Be: change of holder's name

Effective date: 19950906

NLS Nl: assignments of ep-patents

Owner name: CLINICAL DIAGNOSTIC SYSTEMS, INC.

NLT1 Nl: modifications of names registered in virtue of documents presented to the patent office pursuant to art. 16 a, paragraph 1

Owner name: JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC.

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19960216

Year of fee payment: 7

REG Reference to a national code

Ref country code: GB

Ref legal event code: 728V

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19970202

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

REG Reference to a national code

Ref country code: GB

Ref legal event code: 728Y

EUG Se: european patent has lapsed

Ref document number: 90301061.9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20010122

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20010131

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20010213

Year of fee payment: 12

Ref country code: FR

Payment date: 20010213

Year of fee payment: 12

Ref country code: DK

Payment date: 20010213

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20010219

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20010228

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20010313

Year of fee payment: 12

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020201

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020228

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020228

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020228

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020228

BERE Be: lapsed

Owner name: JOHNSON & JOHNSON CLINICAL DIAGNOSTICS INC.

Effective date: 20020228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020901

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020903

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20020201

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20021031

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20020901

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050201